How to Navigate Compassionate Use Programs in Rare Disease Regulation

Introduction: The Role of Compassionate Use in Rare Disease Access

For patients with rare and life-threatening diseases, access to investigational therapies before formal marketing authorization can be life-saving. Compassionate Use—also known as Expanded Access—provides a regulated pathway for patients who are not eligible for clinical trials to receive promising treatments still under investigation.

These programs are especially critical in rare disease landscapes, where standard treatment options are often nonexistent. Regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA) have developed structured approaches to enable this access while maintaining safety and ethical standards.

Understanding the Regulatory Terminology

Compassionate Use varies in name and scope across jurisdictions. Below is a comparison of terms and frameworks:

Each system has slightly different eligibility requirements, documentation, and timelines, but the core principles of unmet need and ethical oversight are universal.

Types of Compassionate Use Access

Expanded access can take several forms depending on the scope and regulatory body:

• Single Patient IND: For individual cases, including emergencies (U.S. FDA)
• Intermediate-size Patient Population: For groups not eligible for a clinical trial
• Treatment IND: For broader access during the drug’s late-stage development
• Named Patient Program (EU): Physicians request unapproved drugs for specific patients
• Group Program: Coordinated use for defined patient categories (e.g., compassionate use for a genetic subtype)

Eligibility Criteria for Compassionate Use

Although terminology and scope vary, the typical eligibility requirements are:

• Patient has a serious or life-threatening condition
• No comparable or satisfactory alternative therapies
• Patient is not eligible for ongoing clinical trials
• Potential benefits outweigh the anticipated risks
• Access will not interfere with the drug’s development program

In all cases, regulatory agencies require submission of safety data, physician certifications, and IRB/ethics committee approvals before treatment begins.

Continue Reading: Application Process, Ethical Considerations, and Global Case Studies

Application Process for Compassionate Use Programs

The process for obtaining access to an investigational product under compassionate use involves multiple steps, which vary by jurisdiction but generally follow a consistent structure:

1. Physician Request: The treating physician initiates the request and confirms that the patient meets eligibility criteria.
2. Sponsor Consent: The drug sponsor must agree to provide the investigational product and often assists with regulatory documentation.
3. Ethics Committee/IRB Approval: Mandatory for protecting patient rights and ensuring ethical justification.
4. Regulatory Submission: A formal application is submitted to the competent authority (e.g., FDA, EMA, Health Canada).
5. Treatment Authorization: Once approved, treatment can begin under strict monitoring and reporting requirements.

In the U.S., the ClinicalTrials.gov platform also allows sponsors to register their expanded access programs to improve transparency.

Ethical and Legal Considerations

Providing investigational drugs outside clinical trials raises several ethical and regulatory questions. Common concerns include:

• Informed Consent: Patients must fully understand that the product is not yet approved, and its safety/efficacy is unproven.
• Equity and Fairness: Access should be based on medical need, not personal connections or geography.
• Impact on Clinical Trials: Widespread use of compassionate use could reduce enrollment in pivotal studies.
• Data Collection: Sponsors must ensure any data collected under compassionate use aligns with GCP and regulatory expectations.

To mitigate these concerns, some sponsors create internal review boards to assess compassionate use requests independently from clinical operations.

Data Reporting and Post-Treatment Obligations

Compassionate use programs require robust documentation and follow-up. Common post-treatment regulatory requirements include:

• Submission of safety reports, including SAEs and SUSARs
• Ongoing benefit-risk assessments and potential adjustments to access criteria
• Annual summaries of patient outcomes for regulatory review
• Final report outlining the scope and results of the access program

EMA expects these reports as part of the pharmacovigilance package during marketing authorization review. FDA may incorporate the findings into approval considerations if collected under proper protocol.

Case Study: Compassionate Use in Spinal Muscular Atrophy (SMA)

In 2017, prior to full approval of a gene therapy for SMA, a compassionate use program was initiated for children with advanced disease stages. The program was administered under an FDA expanded access protocol and EMA’s Named Patient Program. Key features included:

• Centralized eligibility screening to ensure fair allocation
• Strict follow-up requirements for adverse events
• Real-time safety data submission to regulators
• Post-treatment monitoring up to 24 months

The data helped strengthen the marketing application and reassured regulators about the product’s safety and usability outside controlled settings.

Global Challenges and Future Outlook

Despite the value of compassionate use, global implementation faces several challenges:

• Lack of harmonized regulations across countries
• High administrative burden on physicians and sponsors
• Limited awareness among patient communities
• Ethical dilemmas in prioritizing patients for access

Future regulatory reform may focus on creating global access frameworks, simplifying application procedures, and enabling responsible use of real-world data generated from compassionate use.

Conclusion: Balancing Access, Ethics, and Safety

Compassionate Use Programs offer a critical bridge between investigational development and real-world patient need. Especially in rare diseases, where patients face dire prognoses, these programs reflect a balance of innovation, access, and ethical responsibility.

To navigate compassionate use from a regulatory perspective, sponsors and physicians must understand regional frameworks, adhere to ethical standards, and maintain transparent documentation. In doing so, they contribute not just to individual patient care but also to regulatory trust and long-term therapy development.

Ethical Frameworks for Emergency Access to Rare Disease Therapies

The Ethical Imperative of Emergency Access

For patients with rare and life-threatening conditions, time is often the most precious resource. When no approved therapies exist, compassionate use or expanded access to investigational products becomes the only hope. Ethical frameworks ensure that such emergency access is granted fairly, transparently, and with due consideration of both risks and potential benefits. Unlike standard clinical trial enrollment, emergency access prioritizes urgent patient need over controlled study design, creating significant ethical and regulatory challenges.

The central ethical tension lies in balancing patient autonomy and right to treatment against the scientific integrity of clinical development. Without safeguards, expanded access can inadvertently compromise trial recruitment, introduce safety uncertainties, or create inequities in who receives investigational drugs. Ethical frameworks provide the structured guidance needed to manage these dilemmas responsibly.

Key Ethical Principles in Emergency Access

Emergency access frameworks in rare disease contexts are grounded in bioethical principles:

• Beneficence: Acting in the best interest of patients by offering potentially life-saving therapies.
• Non-maleficence: Avoiding undue harm by ensuring appropriate safety monitoring and risk communication.
• Justice: Ensuring equitable access across patient populations regardless of geography, socioeconomic status, or advocacy strength.
• Autonomy: Respecting patients’ informed choices in deciding whether to pursue investigational treatments.

Applying these principles requires structured policies and regulatory oversight that both protect patients and sustain research progress.

Regulatory Pathways for Emergency and Compassionate Use

Different jurisdictions have developed pathways to operationalize emergency access while maintaining regulatory safeguards:

• FDA Expanded Access (U.S.): Allows investigational drug use outside of clinical trials for patients with serious or life-threatening conditions, supported by FDA Form 3926.
• EMA Compassionate Use (EU): Provides national-level programs for pre-approval use of investigational medicines under Article 83 of Regulation (EC) No 726/2004.
• Health Canada Special Access Program: Enables physicians to request drugs not available for sale in Canada for patients with serious or life-threatening conditions.
• Japan’s Expanded Access System: Facilitates access to unapproved drugs on a case-by-case basis, subject to national review.

These programs demonstrate international commitment to balancing patient need with regulatory oversight. A comprehensive listing of compassionate use trials can be found through the EU Clinical Trials Register.

Challenges in Ethical Implementation

Emergency access raises several ethical and operational challenges:

• Equity of Access: Patients with stronger advocacy networks often secure access, while underserved groups may be excluded.
• Data Integrity: Providing investigational drugs outside trials may reduce patient enrollment in pivotal studies, delaying broader approval.
• Safety Oversight: Emergency access patients may not receive the same rigorous monitoring as trial participants.
• Resource Allocation: Limited drug supply in ultra-rare indications may force sponsors to prioritize between trial patients and expanded access requests.

Ethical frameworks must explicitly address these risks by defining transparent eligibility criteria, prioritization systems, and follow-up requirements.

Best Practices for Ethical Emergency Access Frameworks

Several best practices can strengthen ethical management of emergency access:

1. Transparent Eligibility Criteria

Clear guidelines should define which patients qualify, based on disease severity, prior treatment history, and absence of trial availability.

2. Fair Prioritization Systems

When drug supply is limited, allocation systems should avoid favoritism and prioritize based on clinical urgency rather than advocacy influence.

3. Safety and Data Collection

Even outside formal trials, safety monitoring and outcome reporting should be mandatory to contribute to the broader knowledge base.

4. Stakeholder Involvement

Engaging patients, caregivers, advocacy groups, and clinicians in policy design ensures frameworks reflect real-world needs and fairness.

Case Study: Compassionate Access to Enzyme Replacement Therapy

A biotech company developing an enzyme replacement therapy for an ultra-rare lysosomal storage disorder faced limited supply during Phase II trials. To address compassionate use requests, the company created a prioritization algorithm based on severity, disease progression, and trial ineligibility. Independent ethics boards reviewed requests, and all patients receiving emergency access were monitored under a structured registry. This approach not only ensured fairness but also generated valuable real-world safety data that informed regulatory approval.

Future Directions in Ethical Framework Development

Looking ahead, ethical frameworks for emergency access in rare disease therapies are likely to evolve with greater standardization and transparency. Emerging strategies include:

• Global Harmonization: WHO-led initiatives to align compassionate use policies across countries.
• Digital Registries: Blockchain-enabled registries to document compassionate use decisions, ensuring transparency and auditability.
• Patient-Centered Metrics: Incorporating patient-reported outcomes into emergency access programs to balance efficacy with lived experience.

Such innovations can reduce inequities, strengthen oversight, and accelerate approval pathways for therapies urgently needed by rare disease communities.

Conclusion: Balancing Hope with Responsibility

Emergency and compassionate access programs embody the ethical responsibility to offer hope to patients facing life-threatening rare diseases. Yet, without structured frameworks, these programs risk compromising fairness, safety, and scientific progress. By embedding principles of beneficence, justice, and transparency into emergency access models, stakeholders can responsibly balance urgent patient needs with long-term research integrity. Ultimately, ethical frameworks ensure that access to investigational therapies remains both a humanitarian act and a scientifically sound practice.

Leveraging Patient Registries for Regulatory Decision-Making: A Practical Guide

Patient registries have emerged as critical tools in the regulatory landscape, providing real-world data (RWD) to support evidence-based decisions on drug approvals, safety monitoring, and post-marketing commitments. As pharmaceutical professionals and clinical trial experts navigate evolving regulatory expectations, understanding how registries contribute to regulatory decision-making is essential. This tutorial outlines the design, application, and compliance strategies necessary for successful use of registries in regulatory frameworks.

What Are Patient Registries and Why Do They Matter?

Patient registries are organized systems for collecting uniform data to evaluate specified outcomes in defined populations. Unlike clinical trials, registries capture real-world evidence (RWE) over extended periods and diverse settings, offering regulatory bodies longitudinal data on:

• Product effectiveness in real-world use
• Long-term safety trends
• Disease natural history and progression
• Health economics and patient-reported outcomes

Such insights are vital for regulators like the EMA and USFDA in supporting risk-benefit evaluations.

Regulatory Context for Using RWE from Registries:

Global regulatory agencies have issued frameworks acknowledging the value of RWE in approvals and label expansions. For example:

• The USFDA’s Framework for Real-World Evidence (2018)
• EMA’s guidance on registry-based studies and ENCePP resources
• Health Canada’s Drug and Health Product RWE use policy

Regulatory acceptance requires registries to meet specific data quality, relevance, and methodological rigor standards.

Designing Registries with Regulatory Objectives in Mind:

Registries intended for regulatory use should be purpose-built with clearly defined endpoints. Follow these best practices:

1. Engage regulatory experts early in protocol design
2. Use standard terminologies like MedDRA, SNOMED CT, and ICD-10
3. Ensure traceability of data sources and audit trails
4. Document protocols and changes with Pharma SOP documentation

When integrated properly, registries can complement clinical trial data or act as a standalone evidence source in specific regulatory pathways.

Examples of Regulatory Applications Using Registry Data:

Regulatory use cases of patient registries are increasingly common. Examples include:

• Post-approval safety monitoring (e.g., long-term adverse event tracking)
• Label extensions based on registry outcomes
• Rare disease drug evaluations where randomized trials are not feasible
• Real-world comparator arms in single-arm trials

These cases highlight how registries can fill data gaps while aligning with pharma regulatory compliance expectations.

Maintaining Data Quality and Validation Standards:

Data quality is a cornerstone of regulatory acceptance. To ensure reliability, registries must implement:

• Data entry standardization using eCRFs
• Automated edit checks and logical validations
• Periodic monitoring and audit reviews
• Standardized outcome definitions across sites

Validation aligned with validation master plan principles strengthens the registry’s credibility during regulatory reviews.

Ethics, Transparency, and Informed Consent:

Regulatory-grade registries must also uphold high ethical standards. Considerations include:

• Obtaining Institutional Review Board (IRB) approvals
• Ensuring electronic informed consent (eIC) protocols
• Maintaining data de-identification and encryption
• Public transparency through registry listings or publications

Following ICH GCP and data protection regulations like GDPR is essential to uphold credibility and ethical compliance.

Integrating Patient-Centric Measures and Real-World Outcomes:

Modern regulatory decisions value outcomes that reflect patient experiences. Incorporate:

• Quality-of-life instruments (e.g., EQ-5D, SF-36)
• Patient-reported outcomes (PROs)
• Functional assessments
• Adherence and satisfaction metrics

These enrich real-world insights and support more holistic regulatory assessments, especially in chronic or rare diseases.

Data Governance and Audit Readiness:

To be considered during audits or submissions, registries must be audit-ready. Best practices include:

• Version control for all data elements and SOPs
• Role-based user access logs
• Real-time data monitoring dashboards
• Archived datasets with timestamp metadata

Periodic internal audits using a GMP audit process mindset ensures continued readiness and quality assurance.

Statistical Considerations for Regulatory Submissions:

Registries used for regulatory purposes should follow rigorous statistical methods. These include:

1. Propensity score matching to control for confounding
2. Subgroup and sensitivity analyses
3. Survival analysis for time-to-event outcomes
4. Missing data imputation and handling

Document all statistical approaches in the protocol and analysis plan. Include justification for methods during regulatory submission.

Case Study Snapshot: RWE for Rare Diseases

For rare diseases, patient registries often provide the only viable means to gather data. As trial enrollment is difficult, regulators accept registry data for:

• Natural history documentation
• Establishing external controls
• Monitoring compassionate use programs

These cases demonstrate that real-world registries are not just supplemental—they are sometimes foundational for approval pathways.

Conclusion:

Patient registries have evolved into robust, versatile platforms for generating real-world evidence in regulatory settings. When designed with quality, transparency, and regulatory alignment, they offer unparalleled opportunities to support drug approvals, safety assessments, and post-market commitments. As acceptance of RWE grows globally, pharma stakeholders must invest in registry infrastructure, governance, and validation to ensure meaningful contributions to public health and regulatory decision-making.

For support on registry-related data tied to product shelf life or formulation stability, consult resources from StabilityStudies.in.